In this Psychedelic Spotlight exclusive, we speak with California Senator, Scott Wiener (D-San Francisco), to discuss Senate Bill 519 (SB-519) which aims to decriminalize the possession and sharing of certain psychedelics within the state of California, and, on the heels of the bill receiving approval from the State Senate earlier this month.

In our conversation with the Senator, we discuss the impetus behind the Bill’s introduction, what it aims to achieve, and the encouraging, yet challenging, road that still remains ahead for it as it now moves to the State Assembly.

*Get the latest industry news around all things psychedelics by visiting our website and be sure to subscribe to our newsletter to never miss a thing.

Subscribe to our YouTube channel: https://bit.ly/3prTiCI
Visit our Website: https://psychedelicspotlight.com
Follow us on Instagram: https://instagram.com/psycspotlight
Like us on Facebook: https://facebook.com/PsychedelicSpotlight
Follow us on Twitter: https://twitter.com/PsycSpotlight

*This interview was recorded on June 18, 2021.

#california #psychedelics #government

source

Similar Posts

Interview With Dr. Steven Mandel

Interview With Dr. Steven Mandel

Listen, Podcasts

In this episode of the Psychedelic Spotlight podcast, we have the distinct privilege of speaking with one of the foremost experts in ketamine-assisted therapy, Dr. Steven L. Mandel, Founder and President of Ketamine Clinics Los Angeles.

NEW MindMed teaming up With Pfizer, J&J and Johns Hopkins on Digital Medicines? (MNMD, PFE, JNJ)

NEW MindMed teaming up With Pfizer, J&J and Johns Hopkins on Digital Medicines? (MNMD, PFE, JNJ)

Listen, Videos

As technological change revolutionizes medicine and healthcare, how do we ensure that no-one, particularly members of vulnerable groups, get left behind?

This is the question that companies like MindMed (MNMD, MMED) , Johnson and Johnson (JNJ), and Pfizer(PFE) , as well as government organizations like the FDA, and universities like Johns Hopkins are trying to answer through collaborating with each other in a forum called The Digital Health Measurement Collaborative Community, or DATAcc.

Useful links:

https://datacc.dimesociety.org/

https://thecannabisstock.com/2021/08/03/mindmed-joins-digital-medicine-society-to-improve-health-outcomes-and-equity-using-technology/

https://www.prnewswire.com/news-releases/healthcare-leaders-collaborate-on-digital-inclusion-initiatives-301341678.html

Enjoy the episode!

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #JNJ #Pfizer

atai Life Sciences Q2 Conference Call and Questions & Answer Period: BIG NEWS for Psychedelic Stocks

atai Life Sciences Q2 Conference Call and Questions & Answer Period: BIG NEWS for Psychedelic Stocks

Listen, Videos

What’s up psychedelic stocks investors?!? Today marked atai Life Science’s (Nasdaq: atai) first-ever conference call, for Quarter 2, 2021. In the conference call, atai Life Sciences gave updates on their varying projects, ranging from attempting to treat depression, to cognitive impairment associated with schizophrenia. They also give insights on atai’s digital medicines division and answer investor’s questions at the end of the call.

This Peter Thiel-backed psychedelic therapies company is fighting for the title of the most advanced psychedelic stock. With 10+ different projects under their belt, atai is one of the most exciting companies to keep an eye on in the industry.

This conference call can help investors answer the questions: is atai stock a good investment? Will atai go up? Are psychedelic stocks / shroom stocks good investments? Can psychedelics heal depression? Can psychedelics be used for mental health?

Enjoy the episode!

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Check out our website: thepsychedelicinvestor.com

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

#atai #ataiLifeSciences #PsychedelicStocks

Interview with Joseph Mays, IRI Program Director at Chacruna

Interview with Joseph Mays, IRI Program Director at Chacruna

Listen, Podcasts

In our conversation with Joseph, we chat a bit about some critical topics such as how psychedelics can allow us to understand the Indigenous philosophy of interrelatedness between one another and our ecosystems, the importance of considering sacred reciprocity to Indigenous peoples and their land, and how Chacruna’s Indigenous Reciprocity Initiative is making it simple for companies to give back to the societies who have cultivated psychedelic medicine.